Zelboraf Approved for Late-Stage Melanoma
The FDA today approved Zelboraf (vemurafenib) for the treatment of advanced or metastatic melanoma. The drug extends survival for the 50% of melanoma patients whose tumors carry the BRAF mutation.
Click here to read the full story.
No profanity or inappropriate comments will be allowed.
Offensive posters will be blocked from future postings.
The content has been reported and it will be reviewed by a moderator.
